Acute-on-chronic liver failure (ACLF) develops in acute decompensation (AD) of cirrhosis and shows high mortality. In critically ill patients, early diagnosis of ACLF could be important for therapeutic decisions (eg, renal replacement, artificial liver support, liver transplantation). This study evaluated fibroblast growth factor 21 (FGF21) as a marker of mitochondrial dysfunction in the context of ACLF. The study included 154 individuals (112 critically patients and 42 healthy controls) divided into a training and a validation cohort. In the training cohort of 42 healthy controls and 34 critically ill patients (of whom 24 were patients with cirrhosis), levels of FGF21, interleukin (IL) 6, and IL8 were measured. In the validation cohort of 78 patients with cirrhosis, 17 patients were admitted with or developed ACLF during follow-up and underwent daily clinical and nutritional assessment. Levels of FGF21 were higher in critically ill patients, especially in patients with cirrhosis admitted to the intensive care unit (ICU). Moreover, FGF21 as well as IL6 and IL8 levels were higher in patients with ACLF, but they did not increase with the severity of ACLF. Interestingly, in the validation cohort, FGF21 was also elevated in the patients who developed ACLF in the next 7 days. In these patients, FGF21 levels were an independent predictor of ACLF presence and development in multivariate analysis together with Child-Pugh score. FGF21 levels had no impact on the survival of critically ill patients with cirrhosis. In conclusion, this study demonstrates that FGF21 levels are of specific diagnostic value regarding the presence and development of ACLF in patients admitted to ICU for AD of liver cirrhosis. Further studies are warranted to address pathophysiological and possible therapeutic implications.
extrahepatic organ failure and characterized by high mortality ranging from 23% to 74%. (1) In some patients, ACLF can occur early in the course of the disease. In fact, ACLF might be the first presentation of AD in these patients. (1) In particular, younger patients without previously documented AD have shown a severe degree of the syndrome and high mortality.
(1) Moreover, the clinical course of patients admitted to the hospital seems to be important for the prognosis, especially because development of ACLF presents a major crossroad in the clinical evolution and therefore management of the patients. (1) (2) (3) In critically ill patients with cirrhosis, diagnosis of ACLF could play an important role in the timing of several therapeutic decisions, such as renal replacement therapy, plasma exchange, artificial liver support, and liver transplantation. (4) (5) (6) Therefore, early diagnosis of patients with AD, who will develop ACLF after admission to the intensive care unit (ICU), is crucial. (4) Different prognostic scores have been developed to stratify not only the risk of mortality in ACLF patients, (7) but also the risk of mortality in patients with AD but without ACLF. (8) Biomarkers of systemic inflammation, of which interleukin (IL) 6 and IL8 have performed best, (9, 10) characterize presence and prognosis of ACLF. Also, mitochondria play an essential role in cellular energy homeostasis, (11) whereas mitochondrial dysfunction, induced by different mechanisms, is directly linked to cell death and might be responsible-at the cellular level-for the failure of different organs, as occurring in ACLF. Fibroblast growth factor 21 (FGF21) is highly expressed and secreted by the liver and has profound effects on glucose and lipid metabolism. (12, 13) Thus, FGF21 is regarded as a marker of mitochondrial dysfunction and has been used as a biomarker in extrahepatic diseases. (14) (15) (16) (17) This study aimed to evaluate FGF21 as a potential predictor of ACLF development and mortality in this population, and its association with markers of systemic inflammation (IL6, IL8) in critically ill patients with cirrhosis.
Patients and Methods
The objective of this study was to analyze the relationship of FGF21 with ACLF, outcome, and systemic inflammation, as assessed by IL6 and IL8. This study was conducted with 2 cohorts (Fig. 1 ). The training cohort was recruited at the Department of Internal Medicine I, University Clinic Bonn, Bonn, Germany between November 2014 and June 2016. This cohort included 34 critically ill patients recruited at ICU, of whom 24 were patients with cirrhosis and 10 were patients without cirrhosis who were controls, and 42 healthy controls. The validation cohort consisted of 78 patients with cirrhosis recruited at a specialized ICU in a tertiary care center in Mexico City, Mexico, from January to December 2015. The study was designed and conducted according to the principles of the Declaration of Helsinki and was approved by both the institutional ethics committee board (Mexico City, reference number 1347; University of Bonn, 203/13) and all patients or their representatives who signed the informed consent form.
The diagnosis of liver cirrhosis was based on the combination of clinical features, radiological imaging, presence of portal hypertension, compatible biochemical parameters, and/or confirmatory liver biopsy. The admission to the hospital and/or ICU was due to AD defined as described in the EASL-CLIF Acute-onChronic Liver Failure in Cirrhosis (CANONIC) study.
(1) Clinical and biochemical parameters were obtained to assess Child-Pugh score, Model for EndStage Liver Disease (MELD), Model for End-Stage Liver Disease-sodium (MELD-Na), Chronic Liver Failure (CLIF)-ACLF, and CLIF-AD scores. Hepatic encephalopathy (HE) diagnosis was based on the West Haven criteria; ascites was based on the criteria from the International Club of Ascites; and other organ failures were assessed according to the CLIFSequential Organ Failure Assessment (SOFA) score. Astrid Ruiz-Marg ain, Alessandra Pohlmann, and Patrick Ryan participated in the study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and statistical analysis. Christian Jansen, Robert Schierwagen, and Jennifer Lehmann participated in acquisition of data, analysis and interpretation of data, drafting of the manuscript, and statistical analysis. Luis A. ChiCervera, Osvely Mendez-Guerrero, Nayelli C. Flores-Garc ıa, and Aldo Torre participated in acquisition of data; critical revision of the manuscript; and administrative, technical, and material support. Ricardo Ulises Mac ıas-Rodr ıguez and Jonel Trebicka participated in study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript regarding important intellectual content; funding recipient; administrative, technical, and material support; and study supervision.
SCHEDULES OF CLINICAL AND LABORATORY ASSESSMENTS
At inclusion, the training cohort patients underwent clinical and laboratory evaluation and samples of peripheral blood and ascites fluid were collected. After inclusion, all validation cohort patients underwent clinical and nutritional evaluation and blood samples were obtained. Physical examination was performed in every patient to evaluate the presence of cirrhosisrelated complications. Routine biochemical parameters were obtained daily in order to assess the possible presence of other organ failures.
ONSET OF ACLF DEFINITIONS
At admission, prevalence is defined as patients who were admitted to the ICU and already met the diagnostic criteria of ACLF.
Development of ACFL during follow-up is defined as patients who were admitted to the ICU for AD without meeting criteria for ACLF but developed the ACLF syndrome during the hospitalization follow-up.
FGF21, IL6, AND IL8 ASSESSMENT
On the day of inclusion, a sample of peripheral blood was collected in tubes containing ethylene diamine tetraacetic acid, which was immediately centrifuged; the obtained supernatant was stored at -808C. FGF21 was measured as a primary aim, and IL6 and IL8 were measured as secondary aims. Levels of IL6, IL8, and FGF21 were analyzed in the Laboratory for Liver Fibrosis and Portal Hypertension at the University Clinic Bonn using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's guidelines (R&D Systems Inc., Minneapolis, MN). All tests were run in duplicate.
STATISTICAL ANALYSIS
Descriptive statistics were used for baseline characteristics of the population. Kolmogorov-Smirnoff test was used in order to evaluate normality of the variables. To compare groups, Student t, Mann-Whitney U, chisquare, or Fisher's exact tests were used as appropriate. Area under the receiver operating characteristic curves (AUROCs) were constructed to obtain cutoffs. Kaplan-Meier curves were used to evaluate the incidence of ACLF, a log-rank test was used to compare the curves, and finally, logistic regression analysis was done to control different variables. Variables that were significantly associated with ACLF in the univariate analysis were included in the multivariate analysis. Nevertheless, the number of variables included in our model was modified by taking into account the 10-20 events per variable in order to avoid overfitting. The data analysis was carried out using SPSS, version 21 (IBM, Armonk, NY), and Med Calc, version 17.4.4.
Results

CHARACTERISTICS OF THE TRAINING COHORT
A total of 42 healthy controls were recruited together with 34 ICU patients, of whom 10 were critically ill patients without cirrhosis and 24 were critically ill patients with cirrhosis who were admitted with an AD (Table 1) . Of the 24 patients with cirrhosis, 17% were Child-Pugh C with a median score of 8 (range, 5-11), and with a median MELD score of 15 (range, 6-37). Alcoholic liver disease and chronic viral hepatitis were the main etiologies of cirrhosis in this cohort. Of these patients, 25% presented with HE, more than 95% showed severe ascites, and almost 29% had developed spontaneous bacterial peritonitis (SBP). At the time of inclusion, 18 patients had developed ACLF (6 patients, grade 1; 5 patients, grade 2; and 7 patients, grade 3). The main reason for the 10 critically ill patients without cirrhosis to be admitted to ICU was cardiac decompensation (1 patient with dilated cardiomyopathy, 2 patients with non-ST-elevation myocardial infarction, 1 patient with high-grade aortic stenosis, 1 patient with high-grade tricuspid insufficiency, and 1 patient with atrial fibrillation). Two patients with malignant disease (1 case of colorectal carcinoma and 1 case of neuroendocrine tumor) and 2 patients with septic shock (1 due to liver abscess and 1 case of urosepsis) were also included, all of them showing either pleural effusion or ascites. Interestingly, in these patients, SOFA score was 9.9 compared with 9.6 in the patients with cirrhosis. Coagulation parameters, international normalized ratio (INR), and platelet count were significantly worse in the patients with cirrhosis compared with the patients without cirrhosis. Liver function tests were similar, except for bilirubin, which was significantly higher in the patients with cirrhosis (Table 1) . Infection and inflammation parameters were high in both groups: 80% of the patients without cirrhosis and almost 67% of the patients with cirrhosis suffered from some kind of infection. C-reactive protein (CRP) was not significantly lower in the patients with cirrhosis when compared with the patients without cirrhosis, whereas leukocytes tended to not be significantly higher in the group of patients with cirrhosis.
IL6, IL8, AND FGF21 LEVELS IN THE TRAINING COHORT
Compared with the 42 healthy controls, FGF21 was higher in the critically ill patients, with highest levels found in the patients with cirrhosis ( Fig. 2A) . Moreover, when comparing FGF21 levels of patients with cirrhosis with ACLF, their levels were significantly higher than levels in patients without ACLF (Fig. 2B) . This was similar to levels of IL6 (Fig. 2C) and IL8 (Fig. 2D) . However, although FGF21 seems to decrease with the severity of ACLF but remains highly increased compared with non-ACLF patients with cirrhosis, IL6 and IL8 increased with severity of ACLF ( Fig. 2B-D) . Therefore, the FGF21 increase seems to be cirrhosis-and ACLF-specific and an early phenomenon in the development of ACLF. In order to confirm this association of FGF21 with early ACLF, we analyzed a larger validation cohort of patients with cirrhosis.
CHARACTERISTICS OF THE VALIDATION COHORT
In total, 78 patients were included and followed daily for 8 6 6 days during ICU stay. The main cause of admission in the validation cohort were infections (n 5 35; mainly pulmonary tract infections, n 5 19; urinary tract infections, n 5 8; and SBP, n 5 8), followed by variceal bleeding (n 5 27). Of these patients, 72% were Child-Pugh C with a mean MELD score of 22.0 6 7.7. The main etiologies of cirrhosis in this cohort were chronic hepatitis C virus infection, alcoholic liver disease, and autoimmune disease, especially primary biliary cirrhosis and autoimmune hepatitis. Up to 70% of the patients presented some degree of HE, mainly low-grade, and almost 80% presented with ascites, whereas only 17% of the patients had severe ascites (Table 2) .
At the time of admission, 9 patients presented with ACLF, and during the course of hospitalization, 8 more patients developed ACLF. There were no significant differences in the clinical characteristics between these groups (data not shown).
The expected differences between the ACLF and non-ACLF patients regarding Child-Pugh, MELD, and MELD-Na scores as well as levels of creatinine, bilirubin, and INR were observed (Table 2) . Importantly, compared with chronic viral hepatitis patients, significantly more patients with alcoholic cirrhosis developed ACLF, whereas the proportion of patients with other diseases were similar (Table 2) .
ASSOCIATIONS OF FGF21 WITH PRESENCE OF ACLF AND OTHER PARAMETERS
In the validation cohort, FGF21 levels were higher in patients with ACLF (Fig. 3A,B) . Regarding clinical features associated with FGF21 elevation, patients with ascites and malnutrition in the ACLF group had significantly higher values of FGF21 compared with those without ACLF. The same tendency was observed in patients with HE (P 5 0.06) and ACLF (Fig. 4A) . Moreover, higher FGF21 levels correlated significantly with higher MELD (r 5 0.338; P 5 0.01), MELD-Na (r 5 0.374; P < 0.01), and CLIF-SOFA (Fig. 4B) scores. Importantly, FGF21 was not associated with infections (data not shown), but with type of organ failure, showing higher levels in patients with liver failure (1049.2 6 283.6 pg/mL) and renal failure (833.4 6 236.7 pg/mL), whereas the FGF21 levels in patients with cerebral (407.2 6 217.1 pg/mL), circulatory (608.3 6 221.5 pg/mL), and respiratory (554.2 6 279.5 pg/mL) failures were lower. Notably, the inverse correlation with grade of ACLF in the training cohort could not be confirmed in the validation cohort (data not shown).
FGF21 PREDICTION OF ACLF
Not only were FGF21 values significantly higher in patients with ACLF than in patients without ACLF (Fig. 3A) , there was no difference in FGF21 levels in patients with ACLF at admission compared with patients who developed it during follow-up (Fig. 3B) .
To evaluate whether FGF21 could predict ACLF, a receiver operating characteristic (ROC) curve was constructed yielding an overall good cutoff of 309 pg/dL, with a good area under the curve of 0.79 and with 73.3% sensitivity and 72.5% specificity (Fig. 4C) . This cutoff was then applied to the population and was further evaluated in a Kaplan-Meier curve which showed 
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significantly higher incidence of ACLF in patients with FGF21 levels higher than 309 pg/dL compared with patients with levels below this cutoff (Fig. 4D) .
In the univariate analysis, only FGF21, ChildPugh, and MELD score were significantly associated with presence of ACLF. In the multivariate model, both Child-Pugh and FGF21 levels above 309 pg/dL remained independently and significantly associated with the incidence of ACLF (Table 3) .
Finally, the role of FGF21 on mortality was analyzed. Indeed, neither in the univariate nor in the multivariate analysis was FGF21 associated with mortality in these patients. The only independent predictor of mortality in the validation cohort was CLIF-C ACLF score (hazard ratio [HR], 1.271; 95% confidence interval, 1.023-1.580; P 5 0.03).
Discussion
This study describes for the first time the predictive value of FGF21 in diagnosis and prediction of ACLF development in critically ill patients and possibly provides new insight into the role of mitochondrial dysfunction in the development of ACLF.
In the natural history of cirrhosis, the critical step defining the overall outcome is the development of portal hypertension over time, and the presence of complications establishing the appearance of decompensation. (18, 19) However, throughout the course of the disease, patients are prone to develop episodes of AD, triggered by different stimuli. At different stages, patients can develop ACLF, a very severe syndrome in cirrhosis associated with high short-term mortality and defined by the presence of at least 1 organ failure in combination with organ dysfunction. (19, 20) ACLF can present as different clinical settings: in patients admitted to the hospital with AD of cirrhosis, in those admitted with already established ACLF, and even as outpatients, as shown recently. (1, 21) As the syndrome evolves, many of these patients are referred to and treated in the ICU.
(1-4) To date, no specific therapies are available, except for antivirals in the case of ACLF induced by hepatitis B virus flare-ups. (22) This might be due to a lack of understanding of the pathogenesis, but also because in many patients, no obvious trigger can be identified. (23) Nevertheless, some first attempts have been undertaken to nonspecifically treat ACLF by means of liver transplantation, artificial liver support systems, plasma exchange, and granulocyte-colony stimulating factor. (6, 24) Especially in critically ill patients with cirrhosis with an organ failure, the development of other organ failures increases the 90-day mortality from approximately 10% to 50%, as shown in the CANONIC study.
(1) Therefore, biomarkers could help to assess the risk for the development or worsening of ACLF, in order to implement a more aggressive management. (10, 25) Interestingly, to date, the biomarkers used to characterize the ACLF syndrome are inflammatory markers, which are also increased in critically ill patients without cirrhosis and in other inflammatory disorders and are therefore not specific for cirrhosis and ACLF, (9, 26, 27) even though they may correlate with ACLF as previously shown. (28) Besides the previously described IL6 and IL8, FGF21 also was associated with the presence of cirrhosis in the training cohort, and it was also increased in patients with ACLF compared with patients with a single nonrenal organ failure or organ dysfunction. In the pathophysiology of ACLF, persistent and excessive inflammation, as well as an altered immune response are main features of this syndrome. The inflammatory response can alter mitochondrial function, leading to a derangement of the normal processes of this organelle, such as adenosine triphosphate production, maintenance of membrane potential, and regulation of cellular levels of metabolites. Together, this interferes with the electron chain transport, ending up in an increased production of reactive oxygen species and thus perpetuating the damage. (29, 30) FGF21 has been already described as a marker of mitochondrial dysfunction. (12, 13) FGF21 is a peptide hormone involved in multiple metabolic functions and has been associated with antiinflammatory properties in different tissues. (31) Upon liver exposure to different stressors including paracetamol, ethanol, and fat, there is an increase in FGF21 expression, probably trying to attenuate the inflicted damage. (32) Thus, FGF21 is produced in the liver, but in patients without liver cirrhosis and similar SOFA scores, FGF21 levels were significantly lower than in patients with cirrhosis, suggesting a cirrhosis-specific behavior of FGF21. Despite low numbers, this study with healthy controls, critically ill patients without cirrhosis, and patients with cirrhosis with and without ACLF comprehensively analyzed the importance of FGF21 levels as a biomarker for ACLF. Moreover, due to the different etiologies of the patients with cirrhosis, FGF21 seems to occur independent of the cause of liver disease, precipitating event, or genetic background because it has been analyzed in 2 different populations.
The behavior of FGF21 during the course of ACLF was the opposite of IL6 and IL8, already described to be associated with ACLF and increasing with its grade. Therefore, FGF21 could identify patients with cirrhosis with ACLF, especially in its lower grades, which sometimes are difficult to assess, while an increasing number of organ failures is clinically evident. FGF21 might be helpful in distinguishing the presence of ACLF in patients with cirrhosis. These results could be validated and extended in an external validation cohort of critically ill patients. One of the most important findings in the second cohort was that FGF21 was already increased several days before the development of ACLF. Although this study is neither designed nor empowered to uncover a mechanistic or causal relationship between ACLF and FGF21, it nevertheless strongly suggests a close association between FGF21 and ACLF presence and development. It could be speculated that even higher levels of FGF21 are responsible for or reactive to development of organ failures in cirrhosis. On the basis of the CANONIC study, the mechanisms underlying the development of this syndrome seem to be mainly systemic inflammation, altered immune response, and-to some extentcirculatory dysfunction. Especially, the inverse relationship between FGF21, IL6, and IL8 with increasing ACLF grade suggests that this increase occurs independent of systemic inflammation. FGF21 has been linked to mitochondrial dysfunction and glucose and lipid metabolism. (12, 13) Indeed, we confirmed a relationship between FGF21 and malnutrition, ascites and HE in our patients, suggesting that higher levels of FGF21 are at least a readout for dysregulation of cellular energy homeostasis linked to mitochondrial dysfunction. (11) One of the possible explanations for the increase in FGF21 in our study could be a higher production, trying to compensate organ dysfunction during the early setting of inflammation, before the full development of ACLF, as shown by the fact that those patients who developed ACLF during the hospitalization had higher levels of FGF21 at admission, without any other clinical feature suggesting this progression.
FGF21 has been described as a marker of mitochondrial dysfunction in other diseases, (14) (15) (16) (17) and this would underline our observations in 2 independent cohorts. In addition, these data suggest that mitochondrial dysfunction plays a crucial role in the development of organ failure, especially in the presence of cirrhosis, and thus could be a sensitive marker of organ failure in these patients.
A FGF21 cutoff of 309 pg/dL might be suitable to predict development of organ failure(s) in patients with liver cirrhosis, (ie, the development of ACLF). On the other hand, in patients with already established ACLF and FGF21 400 pg/mL, the mortality rate was higher compared with those with levels <400 pg/mL. Finally, in the multivariate analysis only FGF21 and Child score were independent predictors of ACLF development and could outperform previously established scores, such as MELD and CLIF-C AD score. Although these results must be validated in future cohorts, they are nevertheless extremely promising for the diagnosis of ACLF.
This study has several limitations. The relatively low number of patients requires future validation in other cohorts. Moreover, the potential of FGF21 as a biomarker for the prediction of ACLF in noncritically ill patients has not been evaluated. Finally, whether FGF21 increases as the cause or consequence of ACLF and organ failure development is not understood; thus further studies addressing mechanistic pathways are required. Nevertheless, the well-established validation cohort including healthy subjects and the association of the serum values of FGF21 with solid clinical outcomes, including mortality, and replicated in the validation cohort in a different center with different genetic background and etiologies underlines the robustness of this biomarker. However, still not all findings of the training cohort could be validated (eg, the association with the grades of ACLF).
In conclusion, FGF21 is a good predictor of ACLF and organ failure, is quite specific for cirrhosis, and seems independent of etiology and systemic inflammation. This study suggests that mitochondrial dysfunction plays a role in the development of organ failure and ACLF. This could help the clinicians to identify patients at higher risk of ACLF at admittance, and initiate earlier a more intensive therapy, as well as a closer follow-up.
